Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review

IF 3.4 3区医学 Q2 HEMATOLOGY

Therapeutic Advances in Hematology Pub Date : 2024-09-14 DOI:10.1177/20406207241275797

David Yashar, Bernard Regidor, Marissa-Skye Goldwater, Sean Bujarski, Ashley Del Dosso, James R. Berenson

{"title":"Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review","authors":"David Yashar, Bernard Regidor, Marissa-Skye Goldwater, Sean Bujarski, Ashley Del Dosso, James R. Berenson","doi":"10.1177/20406207241275797","DOIUrl":null,"url":null,"abstract":"Despite major therapeutic advancements in recent years, multiple myeloma (MM) remains an incurable disease with nearly all patients experiencing relapsed and refractory disease over the course of treatment. Extending the duration and durability of clinical responses will necessitate the development of therapeutics with novel targets that are capable of robustly and specifically eliminating myeloma cells. B-cell maturation antigen (BCMA) is a membrane-bound protein expressed predominantly on malignant plasma cells and has recently been the target of several novel therapeutics to treat MM patients. This review will focus on recently approved and currently in development agents that target this protein, including bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies. In addition, this protein also serves as a novel serum biomarker to predict outcomes and monitor disease status for MM patients; the studies demonstrating this use of BCMA will be discussed in detail.","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207241275797","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Despite major therapeutic advancements in recent years, multiple myeloma (MM) remains an incurable disease with nearly all patients experiencing relapsed and refractory disease over the course of treatment. Extending the duration and durability of clinical responses will necessitate the development of therapeutics with novel targets that are capable of robustly and specifically eliminating myeloma cells. B-cell maturation antigen (BCMA) is a membrane-bound protein expressed predominantly on malignant plasma cells and has recently been the target of several novel therapeutics to treat MM patients. This review will focus on recently approved and currently in development agents that target this protein, including bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies. In addition, this protein also serves as a novel serum biomarker to predict outcomes and monitor disease status for MM patients; the studies demonstrating this use of BCMA will be discussed in detail.

查看原文本刊更多论文

以 B 细胞成熟抗原为靶点治疗和监测复发/难治性多发性骨髓瘤患者：综述

尽管近年来在治疗方面取得了重大进展，但多发性骨髓瘤（MM）仍然是一种无法治愈的疾病，几乎所有患者在治疗过程中都会出现复发和难治性疾病。要延长临床反应的持续时间和耐久性，就必须开发出具有新靶点的治疗药物，这些靶点能够强效、特异性地清除骨髓瘤细胞。B细胞成熟抗原（BCMA）是一种主要在恶性浆细胞上表达的膜结合蛋白，最近已成为治疗骨髓瘤患者的几种新型疗法的靶点。本综述将重点介绍最近批准和正在开发的针对这种蛋白的药物，包括双特异性抗体、抗体-药物共轭物和嵌合抗原受体 T 细胞疗法。此外，该蛋白还可作为一种新型血清生物标记物，用于预测 MM 患者的预后和监测其疾病状态；将详细讨论证明 BCMA 这种用途的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Hematology HEMATOLOGY-

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.